CNTB (Connect Biopharma) Forvard P/E multiplikatori
Connect Biopharma surunkali yallig'lanish va astma terapiyasi sohasida yetakchi mavqega ega. Kompaniyaning prognoz qilingan P/E koeffitsiyenti kapitalning bozor qiymatini aniq ko'rsatadi, 0.00 esa ushbu metrikaning joriy qiymatini ifodalaydi. Ekspertlar avtoimmun patologiyalarni davolashda brendning xalqaro hamkorlik salohiyatini yuqori baholaydilar. Dermatitga qarshi vositalarga bo'lgan barqaror talab kelajakda emitent uchun barqaror savdo hajmini ta'minlaydi.
Connect Biopharma kompaniyasining tahliliy kesimlari
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- biznesning bozor baholash ko'rsatkichlari:
- balans kapitallashuvi haqida ma'lumot:
- qarzdorlik va likvidlik to'g'risida ma'lumotlar:
Umumiy qarzning xususiy kapitalga nisbati Connect Biopharma|CNTB - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Connect Biopharma|CNTB - Kompaniyaning jamlangan qarzi|Balans kapitallashuviga qarzlar Connect Biopharma Holdings|CNTB - Uzoq muddatli qarz|Kompaniyaning qisqa muddatli qarzlari Connect Biopharma|Tezkor likvidlik connectbiopharm.com
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
CNTB - Kompaniyaning sof daromadi|Kutilayotgan foyda Connect Biopharma|CNTB - Narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Connect Biopharma|CNTB - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|EV/EBITDA multiplikatori Connect Biopharma Holdings|CNTB - Foizlar, soliqlar va eskirishdan oldingi foyda|Bir aksiya uchun sof foyda (EPS TTM) Connect Biopharma|CNTB - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi connectbiopharm.com|CNTB - Joriy yil uchun bitta aksiya uchun sof foyda o'sishi|Keyingi yil uchun bir aksiya uchun kutilayotgan foyda o'sishi Connect Biopharma
Kompaniyaning jamlanma tahliliyoti:Connect Biopharma Holdings Limited
Connect Biopharma (CNTB) salohiyati yallig'lanishga qarshi dori vositalarining klinik sinovlariga asoslangan bo'lib, bu joriy pul oqimi mavjud bo'lmagan holda, kompaniya tahlilchilari hisob-kitoblariga ko'ra oldingi P/E ko'rsatkichini foyda kutimlari bo'yicha asosiy ko'rsatkichga aylantiradi. Ushbu metrika bozor kapitalizatsiyasini kelajakdagi daromadlar bilan solishtiradi, bu esa investorlarga bozorning hissiy barqarorligini baholash va fundamental biznesning inqirozga uchrash xavfini o'z vaqtida aniqlash imkonini beradi.
Connect Biopharma (CNTB) raqobatchilari
Prognoz qilingan narxning foydaga nisbati ARGX (argenx)|BNTX (BioNTech Inc.) - Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori ABVX (abivax.com)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati ADMA Corp (ADMA)|PTGX - Kelajakdagi narxning foydaga nisbati|immunovant.com (IMVT) - Prognoz qilingan narxning foydaga nisbati|Kiniksa (KNSA) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narxning foydaga nisbati Grifols SA|Prognoz qilingan narxning foydaga nisbati ADPT|Forvard P/E multiplikatori Celldex Corp|Kelajakdagi narxning foydaga nisbati Aurinia Pharmaceuticals (AUPH)|biocryst.com - Narxning kelajakdagi foydaga nisbati|Forvard P/E multiplikatori VERA (Vera Therapeutics)|Dianthus Therapeutics Inc (DNTH) - Prognoz qilingan narx-foyda nisbati|Pharvaris Corp - Forvard P/E multiplikatori|AbCellera Biologics (ABCL) - Prognoz qilingan narxning foydaga nisbati|Tourmaline Bio, Inc. (TRML) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati precigen.com (PGEN)|Kelajakdagi narxning foydaga nisbati Pharming Group|Narxning kelajakdagi foydaga nisbati NKTR (Nektar Therapeutics Inc)|Kelajakdagi narxning foydaga nisbati Upstream Bio Corp (UPB)|Zenas Corp - Narxning kelajakdagi foydaga nisbati|Forvard P/E multiplikatori IMNM (Immunome, Inc.)|gossamerbio.com (GOSS) - Prognoz qilingan narx-foyda nisbati|KalVista Pharmaceuticals, Inc. - Forvard P/E multiplikatori|Septerna, Inc. (SEPN) - Prognoz qilingan narxning foydaga nisbati|PVLA (Pieris Pharmaceuticals Inc) - Prognoz qilingan narxning foydaga nisbati|SVRA: Kapitalizatsiyaning kelajakdagi foydaga nisbati|Prognoz qilingan narxning foydaga nisbati RIGL|ANAB: Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori ATXS|Kelajakdagi narxning foydaga nisbati ENGN (enGene Holdings Inc)|Forvard P/E multiplikatori RAPT (RAPT Therapeutics, Inc.)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Aerovate Therapeutics, Inc. (JBIO)|ACRS - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati kyvernatx.com|Tiziana Life Sciences Ltd (TLSA) - Kelajakdagi narxning foydaga nisbati|Narxning kutilayotgan foydaga nisbati CABA (Cabaletta Bio Inc.)|VTYX (Ventyx Bio) - Forvard P/E multiplikatori|THTX: Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori AVTX|Forvard P/E multiplikatori eledon.com (ELDN)|Kelajakdagi narxning foydaga nisbati Agenus Inc. AGEN|Kelajakdagi narx-foyda multiplikatori CLYM|ZURA - Kelajakdagi narxning foydaga nisbati|aTyr Pharmaceuticals (ATYR) - Prognoz qilingan narxning foydaga nisbati|ADAG: Forvard P/E multiplikatori|Ikena Oncology (IMA) - Forvard P/E multiplikatori|STTK (Shattuck Labs Inc) - Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Equillium Bio (EQ)|Kelajakdagi narxning foydaga nisbati Immunic, Inc. (IMUX)|atarabio.com - Narxning kelajakdagi foydaga nisbati|InflaRx - Prognoz qilingan narxning foydaga nisbati|Kapitalizatsiyaning kelajakdagi foydaga nisbati XFOR (x4pharma.com)|Adicet - Forvard P/E multiplikatori|CELU: Kelajakdagi narxning foydaga nisbati|INmune Bio Corp (INMB) - Kelajakdagi narxning foydaga nisbati|Narxning kutilayotgan foydaga nisbati BRNS (Barinthus Biotherapeutics Corp)|KZR (Kezar Life Sciences) - Forvard P/E multiplikatori|SABS: Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori AKTX|Forvard P/E multiplikatori enlivex.com (ENLV)|Kelajakdagi narxning foydaga nisbati Q32 Bio QTTB|Kelajakdagi narx-foyda multiplikatori GOVX|EDSA - Kelajakdagi narxning foydaga nisbati|ibioinc.com (IBIO) - Prognoz qilingan narxning foydaga nisbati|CARM: Forvard P/E multiplikatori|XTL Biopharmaceuticals Ltd (XTLB) - Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati BOLT|HCWB: Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori APVO|Kapitalizatsiyaning prognoz qilingan foydaga nisbati AIM ImmunoTech, Inc.|Kelajakdagi narxning foydaga nisbati Aditxt, Inc. ADTX|GRI - Prognoz qilingan narxning foydaga nisbati|XRTX - Kelajakdagi narxning foydaga nisbati|Vyome Therapeutics (HIND) - Prognoz qilingan narxning foydaga nisbati|REVB (Revelation Biosciences) - Prognoz qilingan narxning foydaga nisbati|indaptusrx.com (INDP) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Scinai Immunotherapeutics Ltd.|Narxning kelajakdagi foydaga nisbati CALI (CalciMedica Corp)|Forvard P/E multiplikatori AFMD|ALLK - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori HOOK (HOOKIPA Pharma)|IGMS - Prognoz qilingan narxning foydaga nisbati|ITOS - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati Ocean Biomedical Inc|TC BioPharm (Holdings) PLC (TCBP) - Kelajakdagi narxning foydaga nisbati|Narxning kelajakdagi foydaga nisbati THRD
